Chad Robins

CEO and Chairman at Adaptive Biotechnologies Corp

Board

Since September 2009

Age

49 years

Education

Holds a BS in Managerial Economics from Cornell University and an MBA from The Wharton School at the University of Pennsylvania.

Tenure

Co-founded ADPT in September 2009 and has served as its CEO and Chairman since its inception.

Also at Adaptive Biotechnologies Corp

Julie Rubinstein

President and Chief Operating Officer

Francis Lo

Chief People Officer

Kyle Piskel

Chief Financial Officer

About

Chad Robins began his distinguished career by holding executive-level positions in the medical technology, investment, and real estate sectors before co-founding Adaptive Biotechnologies in September 2009. His diverse background provided him with a unique perspective that has helped shape the strategic direction of the company.

At ADPT, his leadership has been central to pioneering efforts that translate the genetics of the adaptive immune system into clinical products. Serving as both CEO and Chairman, he has led significant advancements in the company’s MRD and Immune Medicine businesses, driving its growth and positioning it as a leader in the biotechnology industry.

Beyond his role at ADPT, he has contributed his expertise as a board member for several entities, including CM Life Sciences III, Inc. and ARYA Sciences Acquisition Corp II, thereby broadening his impact across the industry. His varied professional journey and strategic insights continue to influence his leadership approach, making a meaningful contribution to both the business and scientific communities in the field.

$ADPT Performance Under Chad Robins

Past Roles

Organization	Role	Date Range	Details
Various Companies	Executive-level positions	Before September 2009	Specific companies and roles not provided

External Roles

Organization	Role	Date Range	Details
CM Life Sciences III, Inc.	Board of Directors	Current	Sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$663,000	Annual	Fixed annual salary
Life Insurance Premiums	$1,316	Annual	Included in All Other Compensation
401(k) Match	$3,000	Annual	Employer contribution to 401(k)
Transportation Services	$18,000	Annual	Transportation benefits provided

Performance Compensation

Data from FY 2023

Annual Incentive Plan (Non-Equity Incentive Compensation)

Metric	Target/Threshold/Max	Weight	Actual Performance	Payout %	Additional Details
Revenue	Threshold: $205M , Target: $205M , Maximum: $235M	40% of Financial Goals (70% of total corporate goals)	$170.3M (Not achieved)	0% (No payout)	Financial goal component
Operating Expense Reduction	Target: $380M	30% of Financial Goals (70% of total corporate goals)	$371.9M (Achieved)	30% (Payout earned)	Financial goal component
MRD (Diagnostic & Clinical Pipelines)	Qualitative assessment	15% of Corporate Goals	Qualitative (Achieved)	15% (Payout earned)	Meets diagnostic and clinical pipeline criteria
Immune Medicine	Qualitative: 2 of 3 goals achieved	15% of Corporate Goals	Qualitative (Achieved)	15% (Payout earned)	Based on qualitative assessment
Employee Engagement	N/A	10% Kicker	Not achieved	0% (No payout)	No payout as employee engagement goals were not met
Overall Corporate Achievement	60% overall	100% total	Overall achievement: 60%	Results in an actual award payout of $318,240	Evaluation based on end-of-year performance

Target Annual Incentive Opportunity: 80% of Base Salary = $530,400.
Actual Earned Incentive: 60% of Target = $318,240.
Vesting Schedule: Cash-based awards with no vesting.
Evaluation Period: Fiscal year 2023 (measured at fiscal year-end).

Long-Term Incentive Program (Equity Awards)

Component	Target Grant Value/Units	Performance Metrics	Vesting Schedule	Evaluation Period	Additional Details
RSUs	Target Grant Value: $3,000,000 <br> Units: 354,610	No specific performance threshold; awarded as part of the 50% mix	Vestes at 25% on each of the first four anniversaries	Measured over multiple years commencing 2023	Part of a 50/50 target mix with PSUs
PSUs	Target Grant Value: $3,000,000 <br> Units: 354,610	Payout Scale: <br> - Below 33rd Percentile: 0% <br> - 33rd Percentile: 50% <br> - 50th Percentile: 100% <br> - 75th Percentile and above: 200%	No vesting schedule; payout based on performance relative to rTSR	Typically assessed over a long-term period starting in 2023	Tied to shareholder return performance relative to a comparator group <br> Grant Date: March 6, 2023 <br> Grant Date Stock Price: $8.46 <br> Aggregate Grant Date Fair Value: $7,900,711

This section provides a comprehensive breakdown of the performance compensation for 2023, covering both non-equity cash awards based on annual performance and the equity-based awards structured to reward long-term shareholder value. All dollar amounts, performance thresholds, and share quantities are based on the 2023 plan details as available in the documents.